Insomnia a sleeping disorder caused by unhealthy sleep habits of a person. Medical conditions that may lead to insomnia are chronic pain, neurological conditions (Parkinson's disease), arthritis, nasal/sinus allergies, gastrointestinal problems, low back pain endocrine problems, asthma and other conditions. It is found to be prevalent among women than in men which may be the results of stress. The Increasing incidence of neurological disorders like Parkinson’s disease favor the growth of this market. The market of insomnia in Europe, the Middle East and Africa is increasing due to increasing insomnia owing to lifestyle changes and use of sleeping pill. Mental stress related to work or other personal issues is found to be another cause leading to insomnia thus favouring the growth of market. Over consumption of sleeping pills may be fatal for the person requiring critical care. Increased psychological and emotional stress is also found to be a major cause of insomnia. Europe, the Middle East and Africa insomnia market is expected to grow at a CAGR of 4.28% during forecasted period of 2017-2023.
The main objective of this research is to provide information about insomnia market in Europe, the Middle East and Africa, its types, drug formulation and type of disease.
Figure 1 Market Assessment
Key Players for Europe, the Middle East and Africa Insomnia market
Pfizer Inc. (U.K), Sanofi (France), GlaxoSmithKline Plc. (UK), Astellas (UK), Biocodex S A (France), Neurim (Switzerland). Others players are Flynn Pharma (UK) CAD Middle East Pharmaceutical Industries LLC (Saudi Arabia), Tabuk Pharmaceutical (Jordan)
Europe, the Middle East and Africa insomnia market has been segmented on the basis of types of therapy which comprises pharmacological therapy and non-pharmacological therapy. Pharmacological therapy is further segmented into benzodiazepines, non-benzodiazepines, melatonin receptor agonists and other. Non pharmacological treatment are further segmented into relaxation therapy, cognitive behavioural therapy, sleep hygiene education, stimulus control, paradoxical intention and other. By drug formulation they are segmented as capsules, tablet and others. On the basis of type of disease they are poor quality of sleep, sleep maintenance and other.
Figure 2- Europe, the Middle East and Africa Insomnia Market, by types of therapy
On regional basis, Europe accounts for accounts the largest share in the Europe, the Middle East and Africa insomnia market. France accounts for the largest market share in insomnia market in Europe. Middle East is the second largest market for insomnia followed by Africa. Increase in prevalence of insomnia, thus resulting in increasing consumption of sleeping pills is the major driving factor for the market in Europe, the Middle East and Africa region.
The report for Europe, the Middle East and Africa insomnia market research report of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.